- Home
- TKLF vs GOVX Comparison
TKLF vs GOVX Comparison
Compare TKLF & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- GOVX
- Stock Information
- Founded
- TKLF 2006
- GOVX 2001
- Country
- TKLF Japan
- GOVX United States
- Employees
- TKLF N/A
- GOVX N/A
- Industry
- TKLF Other Specialty Stores
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- TKLF Consumer Discretionary
- GOVX Health Care
- Exchange
- TKLF Nasdaq
- GOVX Nasdaq
- Market Cap
- TKLF 15.7M
- GOVX 17.4M
- IPO Year
- TKLF 2022
- GOVX N/A
- Fundamental
- Price
- TKLF $3.70
- GOVX $0.68
- Analyst Decision
- TKLF
- GOVX Strong Buy
- Analyst Count
- TKLF 0
- GOVX 3
- Target Price
- TKLF N/A
- GOVX $10.67
- AVG Volume (30 Days)
- TKLF 9.5K
- GOVX 591.0K
- Earning Date
- TKLF 07-10-2025
- GOVX 11-11-2025
- Dividend Yield
- TKLF N/A
- GOVX N/A
- EPS Growth
- TKLF N/A
- GOVX N/A
- EPS
- TKLF 1.57
- GOVX N/A
- Revenue
- TKLF $210,119,238.00
- GOVX $6,143,044.00
- Revenue This Year
- TKLF N/A
- GOVX N/A
- Revenue Next Year
- TKLF N/A
- GOVX N/A
- P/E Ratio
- TKLF $2.35
- GOVX N/A
- Revenue Growth
- TKLF 7.38
- GOVX 1943.07
- 52 Week Low
- TKLF $2.20
- GOVX $0.43
- 52 Week High
- TKLF $6.60
- GOVX $3.88
- Technical
- Relative Strength Index (RSI)
- TKLF 52.45
- GOVX 41.05
- Support Level
- TKLF $3.29
- GOVX $0.67
- Resistance Level
- TKLF $3.77
- GOVX $0.73
- Average True Range (ATR)
- TKLF 0.17
- GOVX 0.04
- MACD
- TKLF 0.03
- GOVX -0.00
- Stochastic Oscillator
- TKLF 79.63
- GOVX 24.14
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.